Piper Jaffray said in a note Monday that Gilead Sciences (GILD) likely won't be impacted by GlaxoSmithKline's (GSK) potential new two-drug HIV regimen.
As if Gilead Sciences (GILD) didn't have enough to worry about with competition in hepatitis C, now the Wall Street Journal is reporting that GlaxoSmithKline (GSK) is attempting to upend the HIV market too. Piper Jaffray's Joshua Schimmer and team don't seem to worried: We have had a number of incoming questions regarding the WSJ article highlighting a potential 2-drug HIV regimen based on GSK's dolutegravir. The costs of HIV resistance are very high, whereas the advantage of a 2-drug regimen over a 3-drug regimen (when both are 1-pill/once daily regimens anyways) is minimal.
GlaxoSmithKline plc (GSK.L)
LSE - LSE Delayed Price. Currency in GBp
|Bid||1,632.50 x 187100|
|Ask||1,650.00 x 336900|
|Day's Range||1,639.50 - 1,653.00|
|52wk Range||1,227.50 - 1,716.50|
|1y Target Est||N/A|
|P/E Ratio (ttm)||2,740.83|
|Avg Vol (3m)||8,779,375|
|Dividend & Yield||N/A (N/A)|